Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+3.97%
+14.76%
-3.92%
-3.26%
-0.18%
CORT
Corcept Therapeutics
$75.73
Strengths
Upgraded on attractively valued
Trading below its fair value
Risk Analysis
Earnings are forecast to decrease
Chart
$83.84 (-9.67%)
$68.2 (+11.04%)
$77.56 (-2.36%)
$50.06 (+51.28%)
CORT has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
CORT overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to decrease
Trading below its fair value
CORT Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CORT Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
ZTS
146.23
+0.77%
SNY
49.75
+0.04%
PBH
62.73
+0.81%
OGN
9.04
-2.06%
NVS
131.25
-0.59%
What is CORT current stock price?
What are CORT stock strengths?
What risks are associated with CORT stock?
When is CORT next earnings report?
What is CORT market cap and volume?
What is CORT's current Stock IQ?
Should I buy CORT stock right now?
Is CORT a Strong Buy right now?
What does a 'Strong Buy' rating mean for CORT?
What does a 'Strong Sell' rating mean for CORT?
What factors influence CORT's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+3.97%
+14.76%
-3.92%
-3.26%
-0.18%
CORT
Corcept Therapeutics
Current Price
$75.73
Stock Insights
Strengths
Upgraded on attractively valued
Trading below its fair value
Risk Analysis
Earnings are forecast to decrease
Linked to CORT
ZTS
146.23
+0.77%
SNY
49.75
+0.04%
PBH
62.73
+0.81%
OGN
9.04
-2.06%
NVS
131.25
-0.59%
Chart
$83.84 (-9.67%)
$68.2 (+11.04%)
$77.56 (-2.36%)
$50.06 (+51.28%)
CORT Analysts Opinion
CORT Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to decrease
Trading below its fair value
CORT Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CORT Street view is bullish and have positive views on the near-term outlook
CORT has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
CORT Latest Analysis
HC Wainwright & Co. Reiterates Corcept Therapeutics (CORT) Buy Recommendation. Fintel reports that on October 20 2025 HC Wainwright &. Co. reiterated coverage of Corcept Therapeutics (NasdaqCM:CORT) with a Buy recommendation. Analyst Price Forecast Suggests 75.31% Upside
Mon Oct 20, 2025
Beyond The Numbers: 6 Analysts Discuss Corcept Therapeutics Stock. Corcept Therapeutics (NASDAQ:CORT) underwent analysis by 6 analysts in the last quarter revealing a spectrum of viewpoints from ish to bearish.The table below offers a condensed view of their recent ratings showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.5100010000200001000011000Providing deeper insights analysts have established 12-month price targets indicating an average targ
Mon Oct 20, 2025
HC Wainwright & Co. Reiterates Corcept Therapeutics (CORT) Buy Recommendation. Fintel reports that on October 10 2025 HC Wainwright &. Co. reiterated coverage of Corcept Therapeutics (NasdaqCM:CORT) with a Buy recommendation. Analyst Price Forecast Suggests 56.13% Upside
Fri Oct 10, 2025
Noteworthy Friday Option Activity: CORT TEM ROKU. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Corcept Therapeutics Inc (Symbol: CORT) where a total of 5951 contracts have traded so far representing approximately 595100 underlying shares. That amounts to about
Fri Oct 10, 2025
Heres What Makes Corcept Therapeutics (CORT) an Attractive Investment?. ClearBridge Investments an investment management company released its Clearbridge Global Value Improvers Strategy second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets reported positive returns in Q2 driven by United States trade deals and expected fiscal stimulus in Europe which countered tariff challenges and geopolitical tensions. Strong contributions from [….]
Fri Oct 3, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CORT Stock trends
CORT Stock performance
CORT Stock analysis
CORT investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.